<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04899687</url>
  </required_header>
  <id_info>
    <org_study_id>60569</org_study_id>
    <nct_id>NCT04899687</nct_id>
  </id_info>
  <brief_title>Study of Dextromethorphan in OCD and Related Disorders</brief_title>
  <official_title>Fluoxetine/Dextromethorphan in Obsessive-Compulsive and Related Disorders: an Open-Label Crossover Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Avy L. &amp; Roberta L. Miller Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in&#xD;
      combination with fluoxetine for symptom relief in OCD and related disorders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obsessive compulsive disorder (OCD) and the related disorders body dysmorphic disorder (BDD),&#xD;
      somatic symptom disorder (SSD) and illness anxiety disorder (IAD) are psychiatric conditions&#xD;
      characterized by recurrent, intrusive thoughts, feelings or images (obsessions or&#xD;
      preoccupations) and repetitive or ritualized behaviors or avoidance performed to relieve&#xD;
      obsession or preoccupation-related anxiety. They are a significant cause of mental&#xD;
      health-related disability, and are inadequately served by available treatments.&#xD;
&#xD;
      This study tests whether an over-the-counter cough suppressant medicine, dextromethorphan,&#xD;
      may offer symptom relief when combined with a low dose of fluoxetine, a standard prescription&#xD;
      treatment for OCD and related disorders.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>After signing consent and baseline assessments, participants will be randomized 1:1 to Group A or Group B for the purposes of sequencing fluoxetine vs combined fluoxetine/dextromethorphan treatment periods.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Symptom rating will be done by independent evaluators blind to treatment allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in OCD or related disorder symptoms as measured by the Y-BOCS</measure>
    <time_frame>Change from baseline will be assessed at 4 weeks and at 8 weeks.</time_frame>
    <description>Improvement in OCD severity is measured by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), a gold standard measure of the severity of obsessions and compulsions. Variants of the Y-BOCS designed for assessment of body dysmorphic disorder or illness anxiety disorder/somatic symptom disorder will be used as appropriate. Y-BOCS scores range from 0 to 40, with higher scores indicating greater severity of symptoms. Response will be defined as a 35% reduction in Y-BOCS score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in clinical insight as measured by the BABS</measure>
    <time_frame>Change from baseline will be assessed at 4 weeks and at 8 weeks.</time_frame>
    <description>Improvement in clinical insight is measured by the Brown Assessment of Beliefs Scale (BABS), a scale assessing multiple dimensions of clinical insight as relevant to OCD and related disorders. The BABS rates multiple dimensions of clinical insight related to an identified belief. BABS scores range from 0-24, with higher scores indicating greater insight impairment. Response will be defined as a 35% reduction in BABS score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obsessive-Compulsive Disorder</condition>
  <condition>Illness Anxiety Disorder</condition>
  <condition>Body Dysmorphic Disorders</condition>
  <condition>Somatic Symptom Disorder</condition>
  <arm_group>
    <arm_group_label>Group A: fluoxetine then fluoxetine plus dextromethorphan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A participants will take fluoxetine 20mg (or prior dose) daily for 4 weeks, and will then continue fluoxetine while adding over the counter dextromethorphan, with doses increasing weekly as tolerated, for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: fluoxetine plus dextromethorphan then fluoxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B participants will take fluoxetine 20mg (or prior dose) daily together with over the counter dextromethorphan, with doses increasing weekly as tolerated, for 4 weeks, and then will stop dextromethorphan, continuing fluoxetine alone for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine</intervention_name>
    <description>Fluoxetine 20mg (or previously prescribed dose) will be taken once daily by mouth for 8 weeks</description>
    <arm_group_label>Group A: fluoxetine then fluoxetine plus dextromethorphan</arm_group_label>
    <arm_group_label>Group B: fluoxetine plus dextromethorphan then fluoxetine</arm_group_label>
    <other_name>Prozac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextromethorphan</intervention_name>
    <description>Dextromethorphan, an over-the-counter cough suppressant, will be taken by mouth twice daily for four weeks of the study, starting at 15mg per dose, and increasing weekly as tolerated to a maximum of 60mg per dose.</description>
    <arm_group_label>Group A: fluoxetine then fluoxetine plus dextromethorphan</arm_group_label>
    <arm_group_label>Group B: fluoxetine plus dextromethorphan then fluoxetine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD),&#xD;
             illness anxiety disorder (IAD) or somatic symptom disorder (SSD)&#xD;
&#xD;
          -  Living within California&#xD;
&#xD;
          -  Capacity to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current bipolar disorder or psychotic disorder&#xD;
&#xD;
          -  Active moderate or severe substance use disorder, lifetime severe substance use&#xD;
             disorder&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Use of prescribed psychotropic medications other than fluoxetine for 2 weeks prior to&#xD;
             study start&#xD;
&#xD;
          -  Having commenced OCD-targeted exposure and response-prevention (ExRP) psychotherapy&#xD;
             within 2 months of study start&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter J van Roessel, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pavithra Mukunda, MS</last_name>
    <phone>650 497 2578</phone>
    <email>ocdresearch@stanford.edu</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 13, 2021</study_first_submitted>
  <study_first_submitted_qc>May 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Peter J van Roessel, MD PhD</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <keyword>OCD</keyword>
  <keyword>BDD</keyword>
  <keyword>IAD</keyword>
  <keyword>SSD</keyword>
  <keyword>Fluoxetine</keyword>
  <keyword>Dextromethorphan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Medically Unexplained Symptoms</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
    <mesh_term>Body Dysmorphic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dextromethorphan</mesh_term>
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

